Active, not recruitingPHASE1, PHASE2NCT03588299

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

Studying Hemophilia A

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bayer
Intervention
BAY2599023 (DTX201)(drug)
Enrollment
11 enrolled
Eligibility
18 years · MALE
Timeline
2018 – 2026

Study locations (13)

Collaborators

Ultragenix pharmaceutical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03588299 on ClinicalTrials.gov

Other trials for Hemophilia A

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia A →

← Back to all trials